Compare CLAR & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLAR | GANX |
|---|---|---|
| Founded | 1957 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.2M | 112.7M |
| IPO Year | 1998 | 2021 |
| Metric | CLAR | GANX |
|---|---|---|
| Price | $2.76 | $2.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $4.81 | ★ $8.00 |
| AVG Volume (30 Days) | 273.0K | ★ 640.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | 11.68 | ★ 47.95 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $228,000.00 | $55,180.00 |
| Revenue This Year | $7.10 | N/A |
| Revenue Next Year | $7.09 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.83 | $1.41 |
| 52 Week High | $4.11 | $4.34 |
| Indicator | CLAR | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 27.79 | 49.87 |
| Support Level | N/A | $1.60 |
| Resistance Level | $3.80 | $2.93 |
| Average True Range (ATR) | 0.13 | 0.27 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 1.80 | 36.41 |
Clarus Corp is a designer, developer, manufacturer, and distributor of outdoor equipment and lifestyle products focused on the climb, ski, mountain, sport, and skincare markets. The company operates through the Outdoor segment, which includes Black Diamond Equipment and PIEPS, is a world-wide leader in designing, manufacturing, and marketing outdoor engineered equipment and apparel for climbing, mountaineering, trail running, backpacking, skiing, and a wide range of other year-round outdoor recreation activities. The Adventure segment, which includes Rhino-Rack, MAXTRAX and TRED, is a manufacturer of engineered automotive roof racks, trays, mounting systems, luggage boxes, carriers, recovery boards and accessories in Australia and New Zealand and United States.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.